Trump, Biogen and Amgen Hammer Healthcare ETFs
March 20, 2017 at 15:05 PM EDT
The initial sell-off came after Trump’s budget blueprint, which signaled higher regulatory costs for the sector and a cut in federal funding for medical research.
